Avantor (AVTR) vs Cytek Biosciences (CTKB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cytek Biosciences (CTKB) has outperformed Avantor (AVTR) over the past year, gaining 40.9% versus a gain of 14.0%. Over five years, AVTR leads with a -60.0% price change compared with -77.8% for CTKB. Avantor is the larger company by market cap ($10.32 billion vs $692.8 million), about 14.9 times the size.
On valuation, Avantor trades at a lower forward P/E (17.4x vs 76.1x for Cytek Biosciences).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTR | CTKB |
|---|---|---|
| Share price | $15.26 | $5.33 |
| Market cap | $10.32B | $692.81M |
| 1-day change | -0.59% | -0.19% |
| YTD return | +33.94% | +5.74% |
| 1-year return | +13.96% | +40.90% |
| 5-year return | -59.97% | -77.81% |
| Forward P/E | 17.39 | 76.14 |
| EPS (TTM) | $-0.84 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.55B | — |
| Revenue growth (YoY) | -3.41% | — |
| Net income (latest FY) | $-530.20M | — |
| Gross margin | 32.65% | — |
| Operating margin | -3.76% | — |
| Net margin | -8.09% | — |
| 52-week high | $16.38 | $6.21 |
| 52-week low | $7.27 | $3.31 |
| Distance from 52-week high | -6.81% | -14.17% |
| Analyst consensus | hold | none |
| Avg. price target upside | -3.15% | +4.32% |
| Average volume | 9.43M | 1.04M |
| Shares outstanding | 676.36M | 129.98M |
| Employees | 13,500 | 682 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Avantor is about 14.9 times larger than Cytek Biosciences by market value ($10.32B vs $692.81M).
- CTKB has outperformed AVTR by 26.9 percentage points over the past year.
About Avantor
AVTR stock →Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.
Industrials · Biotechnology: Laboratory Analytical Instruments · 13,500 employees
About Cytek Biosciences
CTKB stock →Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitate scientific advances in biomedical research and clinical applications. The company offers Cytek aurora, northern lights systems, and Cytek aurora evo systems delivers cell analysis; Cytek Aurora CS System, a cellular complexity to perform additional downstream genomic and proteomic studies using phenotyping approaches; enhanced small particle detection; Cytek amnis imagestream imaging flow cytometers; Cytek guava muse cell analyzers; Cytek muse micro cell analyzers; Cytek guava easyCyte flow cytometers; and Cytek orion reagent cocktail preparation systems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 682 employees
AVTR vs CTKB FAQ
Which is bigger, Avantor or Cytek Biosciences?
Avantor (AVTR) is larger, with a market capitalization of $10.32B compared with $692.81M for Cytek Biosciences (CTKB).
Which stock has performed better over the past year, AVTR or CTKB?
CTKB returned +40.90% over the past 12 months, compared with +13.96% for AVTR (price return, excluding dividends). Past performance does not predict future results.
Are Avantor and Cytek Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.